Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents

Mayo Clinic Proceedings

Volumn 88, Issue 2, 2013, Pages 139-148

  Bowlin, Steven J ^a,c   Xia, Fang ^b   Wang, Wenyi ^a   Robinson, Keisha D ^a   Stanek, Eric J ^a  

^a Medco Health Solutions   (United States)

^b Xia is currently affiliated with Bayer Corporation   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; CYTOCHROME P450; DASATINIB; DEXAMETHASONE; DILTIAZEM; ERLOTINIB; ESOMEPRAZOLE; EVEROLIMUS; FLUCONAZOLE; IMATINIB; INSULIN ASPART; INSULIN GLARGINE; LAPATINIB; LEVOFLOXACIN; METHYLPREDNISOLONE; MOXIFLOXACIN; MULTIDRUG RESISTANCE PROTEIN; NILOTINIB; OMEPRAZOLE; PAZOPANIB; PHENYTOIN; PIOGLITAZONE; PREDNISONE; PRESCRIPTION DRUG; PROMETHAZINE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNINDEXED DRUG;

ARTICLE; DRUG INFORMATION; DRUG INTERACTION; DRUG LABELING; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; ONLINE SYSTEM; PHARMACY; POLYPHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 84876532905     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.10.020     Document Type: Article

References (33)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. http://seer.cancer. gov/csr/1975-2008/.
2. Riechelmann RP, Moreira F, Smaletz Ò, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56(3):286-290.
3. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007; 99(8):592-600. (Pubitemid 47073540)
4. Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage. 2008;35(5):535-543.
5. Puts MTE, Costa-Lima B, Monette J, et al. Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? a prospective pilot study. Drugs Aging. 2009;26(6):519-536.
6. Cashman J, Wright J, Ring A. The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer. 2010;18(5):651-655.
7. Lemachatti J, Levêque D, Beretz L, Bergerat JP. Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients. Anticancer Res. 2009;29(11):4741-4744.
8. Zwart-van Rijkom JEF, Uijtendaal EV, ten Berg MJ, van Solinge WW, Egberts ACG. Frequency and nature of drugdrug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68(2):187-193.
9. Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010;32(5): 575-580.
10. van Leeuwen RWF, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334-2341.
11. Girre V, Arkoub H, Puts MT, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78(3): 220-226.
12. Lam MSH, Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Practice. 2003;9(2-3):45-85. (Pubitemid 37051478)
13. Beijnen JH, Schellens JHM. Drug interactions in oncology. Lancet Oncol. 2004;5(8):489-496. (Pubitemid 39069399)
14. Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20(12):1907-1912.
15. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb; October 2010.
16. Tarceva [package insert]. South San Francisco, CA: Genentech USA Inc; April 2010.
17. Afinitor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; October 2010.
18. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2011.
19. Tykerb [package insert]. Research Triangle Park, NC: GlaxoSmithKline; April 2010.
20. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2011.
21. Votrient [package insert]. Research Triangle Park, NC: GlaxoSmithKline; April 2010.
22. Nexavar [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; March 2011.
23. Sutent [package insert]. New York, NY: Pfizer Inc; July 2010.
24. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). http://medicine.iupui.edu/ clinpharm/ddis/table.aspx. Accessed June 29, 2011.
25. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABC1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-161.
26. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. OpenEpi website. www.OpenEpi.com. Updated June 23, 2011. Accessed January 13, 2012.
27. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011; 12(13):1249-1257.
28. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother. 2007;5(1):31-39. (Pubitemid 47099502)
29. Tamblyn RM, McLeod PJ, Abrahamowicz M, Laprise R. Do too many cooks spoil the broth? multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. Can Med Assoc J. 1996;154(8): 1177-1184. (Pubitemid 26143694)
30. Lu CY, Roughead E. Determinants of patient-reported medication errors: a comparison among seven countries. Int J Clin Pract. 2011;65(7):733-740.
31. Schoen C, Osborn R, Squires D, Doty M, Pierson R, Applebaum S. New 2011 survey of patients with complex care needs in eleven countries finds that care is often poorly coordinated. Health Aff (Millwood). 2011;30(12):2437-2448.
32. Pajares B, Torres E, Trigo JM, et al. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol. 2012;14(2):94-101.
33. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11(1):83-94.